Q4 FY26 Quarterly Activities Report and Appendix 4C
Open PDF
| Stock | VFY.ASX (VFY.ASX) |
|---|---|
| Release Time | 29 Jul 2026, 8:29 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
VFY.ASX Q4 FY26 Quarterly Activities Report and Appendix 4C
Key Points
- Successfully completed USAISR Phase II in-vitro platelets testing with high-quality, 94.4% post-thaw platelet recovery
- Secured partnerships with U.S. blood collection networks Vitalant and Hoxworth
- Completed annual cryopreservation season for aquaculture, increasing throughput year-on-year by ~68%
- Raised $32m via institutional placement and share purchase plan
- Ended the quarter with $41.2m in cash and term deposits
Full Summary
Vitrafy Life Sciences Limited (ASX: VFY) reported its Q4 FY26 Quarterly Activities Report and Appendix 4C Cash Flow report, highlighting successful completion of USAISR Phase II in-vitro platelets testing with 94.4% post-thaw platelet recovery, new partnerships with U.S. blood collection networks Vitalant and Hoxworth, increased aquaculture throughput by ~68% year-on-year, and a $32m capital raise via institutional placement and share purchase plan. The company ended the quarter with $41.2m in cash and term deposits.
Outlook
Vitrafy is focused on securing FDA medical device registration, establishing U.S. manufacturing, and building out resources to serve the U.S. market.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In